RHJA
RETA

Rice Hall James & Associates’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Rice Hall James & Associates’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-114,806
Closed -$11.6M – 323
2021
Q3 		$11.6M Sell
114,806
-2,843
-2% -$333K 0.43% 64
2021
Q2 		$16.7M Sell
117,649
-17,074
-13% -$1.93M 0.59% 56
2021
Q1 		$13.4M Sell
134,723
-1,105
-0.8% -$129K 0.44% 60
2020
Q4 		$16.8M Sell
135,828
-37,464
-22% -$4.92M 0.59% 53
2020
Q3 		$16.9M Buy
173,292
+45,654
+36% +$5.7M 0.68% 46
2020
Q2 		$19.9M Buy
127,638
+26,712
+26% +$4.06M 0.85% 35
2020
Q1 		$14.6M Sell
100,926
-3,423
-3% -$661K 0.81% 38
2019
Q4 		$21.3M Sell
104,349
-2,619
-2% -$478K 0.72% 44
2019
Q3 		$8.59M Sell
106,968
-2,163
-2% -$184K 0.31% 107
2019
Q2 		$10.3M Sell
109,131
-6,787
-6% -$586K 0.34% 102
2019
Q1 		$9.91M Buy
+115,918
New +$9.62M 0.32% 108

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Rice Hall James & Associates's RETA Position: Q4 2021 in Review

Rice Hall James & Associates sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 114,806 shares — an estimated $11.6M sold.

Rice Hall James & Associates first reported a position in RETA in Q1 2019 and held it in 11 quarters. The position peaked at $21.3M in Q4 2019. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.

  • Rice Hall James & Associates reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
  • Rice Hall James & Associates sold 114,806 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $11.6M.
  • Rice Hall James & Associates first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 11 quarters.
  • Rice Hall James & Associates's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $21.3M in Q4 2019.
  • 151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.

Based on Rice Hall James & Associates's 13F filing for Q4 2021, filed 14 Feb 2022.